N.E.W. Advisory Services LLC Invests $75,000 in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

N.E.W. Advisory Services LLC purchased a new position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 868 shares of the company’s stock, valued at approximately $75,000.

Other large investors have also recently made changes to their positions in the company. Park Square Financial Group LLC bought a new position in shares of Invesco Pharmaceuticals ETF in the fourth quarter worth $83,000. Bank of Montreal Can boosted its holdings in shares of Invesco Pharmaceuticals ETF by 48.7% in the fourth quarter. Bank of Montreal Can now owns 1,044 shares of the company’s stock worth $86,000 after acquiring an additional 342 shares during the period. Valley National Advisers Inc. bought a new position in shares of Invesco Pharmaceuticals ETF in the first quarter worth $204,000. Obermeyer Wealth Partners bought a new position in shares of Invesco Pharmaceuticals ETF in the fourth quarter worth $306,000. Finally, JPMorgan Chase & Co. raised its position in shares of Invesco Pharmaceuticals ETF by 6.3% in the fourth quarter. JPMorgan Chase & Co. now owns 4,301 shares of the company’s stock worth $355,000 after buying an additional 255 shares in the last quarter.

Invesco Pharmaceuticals ETF Stock Performance

Shares of PJP stock opened at $82.42 on Thursday. Invesco Pharmaceuticals ETF has a 52-week low of $72.25 and a 52-week high of $89.87. The company has a market capitalization of $238.19 million, a PE ratio of 15.59 and a beta of 0.66. The business’s fifty day moving average is $81.37 and its 200 day moving average is $82.31.

Invesco Pharmaceuticals ETF Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.